In January 2021, the healthcare industry reported 70 deals worth $6.2 billion as compared to last 12-month average (January 2020 to December 2020) of 87 deals worth $17.1 billion.
Sanofi, a pharma company to acquire Kymab, a clinical-stage biopharma company focusing on developing fully human monoclonal antibody therapeutics for approximately $1.4 billion; Angelini Pharma, a pharma company to acquire Arvelle Therapeutics, a biopharma company for $960 million; Thermo Fisher Scientific, to acquire Henogen S.A., a biotech company for $880.8 million and Nordic Capital, to acquire Advanz Pharma Corp, a pharma company for $846 million were some of the major deals that contributed 66 per cent of the total deal value during January 2021.
|
Deal Date |
Acquirer (s) |
Target |
Deal Value ($ m) |
|
11-Jan-21 |
Sanofi (France) |
Kymab Ltd (UK) |
1,450.0 |
|
4-Jan-21 |
Angelini Spa (Italy) |
Arvelle Therapeutics GmbH (Switzerland) |
960.0 |
|
15-Jan-21 |
Thermo Fisher Scientific Inc (US) |
Henogen S.A. (Belgium) |
880.8 |
|
27-Jan-21 |
Nordic Capital Ltd (Sweden) |
Advanz Pharma Corp Ltd (UK) |
846.0 |
|
8-Jan-21 |
Chimerix Inc (US) |
Oncoceutics Inc (US) |
438.0 |
VC investments decreased by three per cent in January 2021, compared to December 2020
The healthcare industry reported 77 venture capital (VC) deals worth $4.4 billion in January 2021, compared to last 12-month average (January 2020 to December 2020) of 124 deals worth $3.2 billion.
EQRx, a biotechnology company raising $500 million in series B financing round for the development of late-stage cancer therapies, pipeline expansion and business growth; Affinivax, a clinical stage biopharma company raising $226 million in series C round of financing to advance its pipeline of Novel MAPS vaccines targeting infectious diseases and New Amsterdam Pharma, a clinical stage company raising $196 million in series A round of financing to support the Phase 3 development of its ApoB and LDL-c lowering small molecule drug—obicetrapib—are the major VC deals reported in January 2021.
|
Deal Date |
Acquirer (s) |
Target |
Deal Value ($ m) |
|
11-Jan-21 |
Nextech Invest Ltd; Arboretum Ventures LLC; ARCH Venture Partners LP; Andreessen Horowitz LLC; Casdin Capital LLC; Section 32; GV Management Co LLC; Undisclosed Investor |
EQRx Inc (US) |
500.0 |
|
8-Jan-21 |
BlackRock Inc; Viking Global Investors LP; Wellington Management Company LLP; EcoR1 Capital LLC; HealthCare Ventures LLC; Foresite Capital Management LLC; Perceptive Advisors LLC; Cormorant Asset Management LLC; Rock Springs Capital Management LP; Bain Capital Life Sciences; T Rowe Price Associates Inc; Surveyor Capital Ltd; Logos Global Management LLC |
Affinivax Inc (US) |
226.0 |
|
14-Jan-21 |
Medpace Inc; Forbion Capital Partners Management Services BV; Morningside Ventures; Peter Thiel; JVC Investment Partners LLC; GL Capital Group; BVF Partners LP; Kaiser Foundation Hospitals (Inactive); Janus Henderson Investors; Presight Capital; Population Health Partners LLC; Ascendant BioCapital; LSP Dementia Fund |
New Amsterdam Pharma BV (Netherlands) |
196.0 |
|
7-Jan-21 |
Wellington Management Company LLP; Omega Fund Management LLC; Orbimed Advisors LLC; Undisclosed Investor(s); Nextech Invest Ltd; EcoR1 Capital LLC; Atlas Venture Inc; Abingworth LLP; Boxer Capital LLC; Casdin Capital LLC; Invus LP; Janus Henderson Investors; Vida Ventures LLC; Surveyor Capital Ltd; Logos Global Management LLC; Woodline Partners |
Scorpion Therapeutics Inc. (US) |
162.0 |
|
13-Jan-21 |
Kurma Partners SA; RA Capital Management, LP; Novo Seeds; Sunstone Capital A/S; HBM Healthcare Investments Ltd; IDInvest Partners; Samsara BioCapital LLC; Vivo Capital LLC; Soleus Capital Management LP; Avoro Capital Advisors LLC; EIR Ventures; Serrado Capital LLC; PFM Health Sciences LP; Lundbeckfonden Emerge |
IO Biotech ApS (Denmark) |
154.5 |